share_log

Juva Life Reports Strong Growth in Q3 2023 Financial Results

Juva Life Reports Strong Growth in Q3 2023 Financial Results

Juva Life公佈2023年第三季度財務業績強勁增長
Accesswire ·  2023/12/13 16:00

REDWOOD CITY, CA / ACCESSWIRE / December 13, 2023 / Juva Life Inc. (CSE:JUVA)(OTCQB:JUVAF)(FRANKFURT:4VV) ("Juva Life" or the "Company"), Juva Life, Inc, a life science company with both pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, is delighted to announce its financial results for the third quarter ending September 30, 2023.

加利福尼亞州雷德伍德城/ACCESSWIRE/2023年12月13日/Juva Life Inc.(CSE: JUVA)(OTCQB: JUVAF)(法蘭克福:4VV)(“Juva Life” 或 “公司”),Juva Life, Inc.是一家在大麻生產和分銷方面兼具藥物研發和麪向消費者的業務的生命科學公司,很高興地宣佈其第三季度的財務業績將於 2023 年 9 月 30 日結束。

Key Highlights:

主要亮點:

  • Revenue Growth: Juva Life reported a substantial increase in sales, with Q3 2023 sales reaching $3.17 million, compared to $1.25 million for the same period in 2022.
  • Cost Reduction: The company successfully reduced its net loss for Q3 2023 to $782K, a significant improvement compared to a net loss of $2.9 million in Q3 2022.
  • Operational Expansion: The completion of construction and full operational capability at the San Juan Facility in Stockton, California, has contributed to increased cultivation, manufacturing, distribution capacity, and a related increase in revenue.
  • Retail Growth: The addition of a retail store, operational as of June 2023, at the intersection of Broadway and Hamilton streets in Redwood City, CA, has further expanded Juva's presence, complementing its delivery services throughout the Bay Area Peninsula.
  • 收入增長:Juva Life報告銷售額大幅增長,2023年第三季度的銷售額達到317萬美元,而2022年同期爲125萬美元。
  • 降低成本:該公司成功將其2023年第三季度的淨虧損減少至78.2萬美元,與2022年第三季度的淨虧損290萬美元相比,有了顯著改善。
  • 業務擴張:位於加利福尼亞州斯托克頓的聖胡安工廠竣工並具備全面運營能力,促進了種植、製造、分銷能力的提高以及相關的收入增長。
  • 零售增長:在加利福尼亞州雷德伍德城的百老匯街和漢密爾頓街交匯處增加了一家零售店,該商店將於2023年6月開始運營,這進一步擴大了Juva的影響力,補充了其在整個灣區半島的送貨服務。

Financial Overview:

財務概述:

  • Sales: Sales for the nine months ended September 30, 2023 reached $6.4 million, a 52.3% increase over the $4.2 million in revenue for the same period in 2022.
  • Net Loss: The net loss for the nine months ended September 30, 2023, was $4.2 million, a substantial improvement from the $7.9 million loss in the corresponding period in 2022.
  • 銷售額:截至2023年9月30日的九個月中,銷售額達到640萬美元,比2022年同期的420萬美元收入增長了52.3%。
  • 淨虧損:截至2023年9月30日的九個月中,淨虧損爲420萬美元,較2022年同期的790萬美元虧損大幅增加。

Operational Efficiencies:

運營效率:

  • EBITDA Improvement: Despite the challenges in the industry, Juva Life achieved positive strides in operational efficiencies, with EBITDA improving from a negative $4.97 million in Q3 2022 to negative $141K in Q3 2023.
  • Adjusted Gross Margin: The adjusted gross margin for Q3 2023 reached $1.4 million compared to $377K in the same quarter of the previous year.
  • 息稅折舊攤銷前利潤改善:儘管行業面臨挑戰,但Juva Life在運營效率方面取得了積極進展,息稅折舊攤銷前利潤從2022年第三季度的負497萬美元提高到2023年第三季度的負14.1萬美元。
  • 調整後毛利率:2023年第三季度調整後的毛利率達到140萬美元,而去年同期爲37.7萬美元。

Doug Chloupek, CEO and Founder of Juva Life, stated, "We are thrilled to announce our outstanding Q3 results and the successful execution of our strategic initiatives. The robust performance of our Redwood City retail store, coupled with operational achievements in our cultivation and distribution facility, reflects our commitment to innovation and operational excellence."

Juva Life首席執行官兼創始人道格·克洛佩克表示:“我們很高興地宣佈,我們出色的第三季度業績以及戰略計劃的成功執行。我們的Redwood City零售商店的強勁表現,加上我們在種植和分銷設施方面的運營成就,反映了我們對創新和卓越運營的承諾。”

ON BEHALF OF THE BOARD,
-Doug Chloupek-
Doug Chloupek, CEO and Founder

代表董事會,
-Doug Chloupek-
道格·克洛佩克,首席執行官兼創始人

Juva Life Inc.
inquiries@juvalife.com

Juva Life Inc.
inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

關於 Juva Life Inc.(CSE:JUVA)(OTCQB:JUVAF)(FRA:4VV)

Juva Life is employing state-of-the-art pharmaceutical research and development to discover, develop and commercialize safe and effective cannabis products. The Company will leverage revenue derived from its retail operations to advance potentially valuable non-cannabinoid bioactives for consumer and pharma product applications. Find out more at:

Juva Life正在利用最先進的藥物研發來發現、開發和商業化安全有效的大麻產品。該公司將利用其零售業務獲得的收入,爲消費品和藥品應用開發具有潛在價值的非大麻素生物活性。要了解更多信息,請訪問:

For further information, please contact:

欲了解更多信息,請聯繫:

Juva Life Investor Relations
Tel: +1 833-333-5882 (JUVA)
Email: inquiries@juvalife.com

Juva Life 投資者關係
電話: +1 833-333-5882 (JUVA)
電子郵件:inquiries@juvalife.com

SOURCE: Juva Life Inc.

來源:Juva Life Inc.


View the original press release on accesswire.com
在 accesswire.com 上查看原始新聞稿

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論